Medicine information CAMCEVI 42mg prolonged-release suspension for injection
- Product code:
- W68882001
- Quantity:
- 1
- Indicated for:
- prostate cancer; breast cancer; endometriosis
- Route of administration:
- injectable
- Substance:
- leuprorelin (GnRH agonist)
- ATC
- L02AE02 — Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
General data about CAMCEVI 42mg
- Substance:
- leuprorelin
- Date of latest medicines list:
- 01-10-2026
- Product code:
- W68882001
- Strength:
- 42mg
- Pharmaceutical form:
- prolonged-release suspension for injection
- Quantity:
- 1
- Product type:
- Generic medicine
- Price:
- 1843.46 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for leuprorelin
Strengths available for leuprorelin
- 11.25mg
- 22.5mg
- 3.75mg
- 42mg
- 45mg
- 5mg
- 7.5mg
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
The correspondence between the document and the displayed text is unconfirmed.
- Source institution
- EMA
- Document language
- English
- Source record: first published
- 20/06/2022
- Source record: last updated
- 15/09/2026